CompletedPhase 2/3

Effect of Dehydroepiandrosterone (DHEA) on Hot Flashes in Postmenopausal Women

Canada50 participantsStarted 2005-08

Plain-language summary

The purpose of the study is to evaluate the effect of daily oral intake of DHEA 50 mg for 4 months on reducing vasomotor symptoms (hot flashes) compared to placebo administration in postmenopausal women.

Who can participate

Age range40 Years – 70 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy postmenopausal women with 50 or more moderate to severe hot flushes. * Women between 40 to 70 years of age. Exclusion Criteria: * Body mass index (BMI) of 35 kg/m2 or more. * Significant metabolic and endocrine diseases. * Diagnosis of cancer. * Use of steroids or drugs that interfere with the metabolism of estrogen. * Use of any systemic estrogen, progestin, or DHEA in the eight weeks prior to randomization. * Use of alternative therapies or natural products to treat postmenopausal symptoms in the four weeks prior to randomization. * Palpable fibroids or uterine prolapse: Grade 2 or 3. * Cigarette smoking

What they're measuring

Use of a diary to monitor the number and intensity of hot flashes as compared to placebo at screening, day 1, weeks 2, 4, 8, 12 and 16

Trial details

NCT IDNCT00317148

SponsorCHU de Quebec-Universite Laval

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-09

View on ClinicalTrials.gov More Hot Flashes trials